Related Experiment Video
Updated: Oct 27, 2025
06:34
Generation of hiPSC-Derived Intestinal Organoids for Developmental and Disease Modelling Applications
Published on: March 8, 2024
3.1K
A method for constructing GLP-1 overexpression intestinal organoids
Zhi-Yang Zeng1, Jia-Wei Lu1, Xi-Ya Cao1
1Shanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal University, Shanghai 200241, China.
Yi Chuan = Hereditas
|July 21, 2021
Summary
Researchers developed GLP-1 overexpressing mouse intestinal organoids. These organoids enhanced glucose tolerance in mice, offering a potential new treatment strategy for type 2 diabetes.
Area of Science:
- Endocrinology and Metabolism
- Gastroenterology
- Regenerative Medicine
Background:
- Glucagon-like peptide 1 (GLP-1) is a key hormone regulating blood glucose by stimulating insulin release.
- GLP-1 analogs are promising for type 2 diabetes treatment, but novel delivery strategies are needed.
- Intestinal organoids offer a model for studying gut hormone function and developing therapeutic approaches.
Purpose of the Study:
- To construct mouse intestinal organoids engineered to overexpress glucagon-like peptide 1 (GLP-1).
- To evaluate the therapeutic potential of GLP-1 overexpressing organoids in improving glucose homeostasis.
- To establish a novel in vitro model for investigating GLP-1-based diabetes therapies.
Main Methods:
- Optimized lentivirus infection to achieve GLP-1 overexpression in mouse intestinal organoids.
- Cultured GLP-1 overexpressing organoids and collected their secreted supernatants.
- Administered organoid supernatants to wild-type and diabetic mice to assess effects on glucose tolerance.
Main Results:
- Successfully generated mouse intestinal organoids with enhanced GLP-1 expression.
- Supernatants from GLP-1 overexpressing organoids significantly improved glucose tolerance in both wild-type and diabetic mouse models.
- Demonstrated the biological activity and therapeutic potential of the engineered organoids.
Conclusions:
- Engineered GLP-1 overexpressing intestinal organoids represent a viable novel strategy for type 2 diabetes treatment.
- This approach may offer a new avenue for cell-based or secreted factor-based therapies for metabolic disorders.
- The study provides a foundation for further development of organoid-based therapeutic systems for diabetes.
